ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

09 Dec 2024 09:00 CET

Tromsø, Norway, December 9, 2024 - ArcticZymes Technologies (OSE:AZT) introduces
two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed
specifically to meet the evolving demands of the cell, gene and vaccine
biomanufacturing sector.

The new SAN HQ ELISA SensoPlus represents a next-generation innovation for
detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing
processes. With over a fivefold increase in sensitivity compared to its
predecessor, this ELISA kit ensures precise monitoring while offering
significant workflow benefits. Features such as a reusable format, reduced assay
execution times, and lower costs make it an invaluable tool for streamlining
biomanufacturing operations.

Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version
of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects
ArcticZymes' commitment to expanding its portfolio of high-performance
nucleases, providing biomanufacturers the flexibility to select solutions
tailored to their unique production needs. By adding GMP variants to its
portfolio, ArcticZymes is proactively addressing the increasingly stringent
regulatory requirements of the biomanufacturing industry, enabling partners to
achieve compliance with global standards while optimizing their production
processes.

"With SAN HQ ELISA SensoPlus and SAN HQ GMP neo, we are responding to the
critical performance and regulatory demands of the cell, gene, and vaccine
biomanufacturing markets," said Michael Akoh, CEO of ArcticZymes. "These
innovations underscore our dedication to empowering biomanufacturers with
reliable, high-quality tools that facilitate compliance and operational
efficiency. ArcticZymes continues to solidify its role as a trusted partner for
global leaders in therapeutic development and production."

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who developing therapeutics,
in vitro diagnostics, and molecular research kit products. Our mission is to
make our customer's lives easier by unlocking new solutions to enhance quality
of life and create a more sustainable, healthy world.

More information:
Access the news on Oslo Bors NewsWeb site

634132_Launch_of_new_products.pdf